Last Updated:
10 Mar 2026, 03:30:02 PM (IST)
Venus Remedies Limited
NSE: VENUSREM BSE: VENUSREM
NSE
783.40
27.35 (3.62%)
Prev Close
756.05
Open Price
771.9
Volume
70,245
Today Low / High
760.9 / 800
52 WK Low / High
277.95 / 839.95
Range
744 - 823
BSE
784.65
29.40 (3.89%)
Prev Close
755.25
Open Price
769.9
Volume
2,840
Today Low / High
764.05 / 799.8
52 WK Low / High
277.85 / 872.8
Range
745 - 824
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 783.4 (target range: 744 - 823), reflecting a change of 27.35 (3.61749%). On the BSE, it is listed at 784.65 (target range: 745 - 824), showing a change of 29.4 (3.89275%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Venus Remedies Limited Graph
Venus Remedies Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Venus Remedies Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 783.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 784.65 | 792.50 | 713.25 - 871.75 |
| 800.34 | 640.27 - 960.41 | ||
| 808.19 | 565.73 - 1,050.65 | ||
| Bearish Scenario | 784.65 | 776.80 | 699.12 - 854.48 |
| 768.96 | 615.17 - 922.75 | ||
| 761.11 | 532.78 - 989.44 |
Overview of Venus Remedies Limited
ISIN
INE411B01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
32,486
Market Cap
8,707,924,333
Last Dividend
0
Official Website
IPO Date
2006-12-20
DCF Diff
-854.56
DCF
1,506
Financial Ratios Every Investor Needs
Stock Dividend of VENUSREM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2013-09-23 | September 23, 13 | 3 | 3 | 2013-09-24 | 2013-10-30 | 2013-05-20 |
| 2012-09-20 | September 20, 12 | 3 | 3 | 2012-09-22 | 2012-10-28 | 2012-06-21 |
| 2011-09-22 | September 22, 11 | 3 | 3 | 2011-09-24 | 2011-10-30 | 2011-07-26 |
| 2010-09-23 | September 23, 10 | 3 | 3 | 2010-09-24 | 2010-10-27 | 2010-07-31 |
| 2009-09-17 | September 17, 09 | 3 | 3 | 2009-09-19 | 2009-10-30 | 2009-08-21 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 647.89 Cr | 481.62 Cr | 166.27 Cr | 0.2566 | 18.08 Cr | 175.76 Cr | 41.03 Cr | 45.32 Cr | 33.90 | 94.41 Cr | 0.0700 |
| 2024-03-31 | 591.45 Cr | 373.19 Cr | 218.26 Cr | 0.3690 | 15.84 Cr | 12.77 Cr | 33.16 Cr | 28.49 Cr | 21.31 | 71.18 Cr | 0.0482 |
| 2023-03-31 | 555.51 Cr | 330.99 Cr | 224.52 Cr | 0.4042 | 22.89 Cr | 11.56 Cr | 27.32 Cr | 26.57 Cr | 19.87 | 70.35 Cr | 0.0478 |
| 2022-03-31 | 598.65 Cr | 398.24 Cr | 200.41 Cr | 0.3348 | 23.03 Cr | 9.11 Cr | 28.10 Cr | 40.72 Cr | 30.86 | 70.14 Cr | 0.0680 |
| 2021-03-31 | 548.12 Cr | 351.96 Cr | 107.25 Cr | 0.1957 | 15.76 Cr | 11.16 Cr | 10.88 Cr | 61.77 Cr | 50.04 | 96.85 Cr | 0.1127 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 80.10 Cr | 715.72 Cr | 154.77 Cr | 560.9500 Cr | 1.69 Cr | -78.41 Cr | 100.49 Cr | 151.09 Cr | 0.00 Cr | 0.00 Cr | 5.72 Cr | 136.2900 Cr |
| 2024-03-31 | 48.96 Cr | 626.82 Cr | 139.27 Cr | 487.5501 Cr | 41.33 Cr | -7.63 Cr | 121.69 Cr | 155.30 Cr | 0.00 Cr | 0.00 Cr | 4.52 Cr | 79.4158 Cr |
| 2023-03-31 | 21.21 Cr | 601.08 Cr | 140.74 Cr | 460.3400 Cr | 42.29 Cr | 21.08 Cr | 119.94 Cr | 162.82 Cr | 27.03 Cr | 0.00 Cr | -50.89 Cr | 82.5700 Cr |
| 2022-03-31 | 43.26 Cr | 579.82 Cr | 139.37 Cr | 440.4464 Cr | 42.85 Cr | -0.41 Cr | 125.64 Cr | 178.63 Cr | 33.12 Cr | 0.00 Cr | 1.57 Cr | 92.7385 Cr |
| 2021-03-31 | 28.88 Cr | 555.85 Cr | 155.57 Cr | 400.2837 Cr | 51.32 Cr | 22.44 Cr | 119.99 Cr | 190.82 Cr | 20.62 Cr | 0.00 Cr | 4.00 Cr | 97.4451 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.9200 Cr | -80.7900 Cr | -0.9500 Cr | 81.2900 Cr | 27.7706 Cr | 80.1000 Cr | -18.0800 Cr | 45.3200 Cr | -0.9500 Cr | 0.0000 Cr | 0.0000 Cr |
| 2024-03-31 | 37.2853 Cr | -7.2093 Cr | -1.0827 Cr | 27.8400 Cr | 27.7436 Cr | 48.9558 Cr | -9.3182 Cr | 28.4908 Cr | -0.9891 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | 36.6200 Cr | -50.8300 Cr | -0.5700 Cr | 28.8020 Cr | -22.0500 Cr | 21.2100 Cr | -7.8180 Cr | 37.9300 Cr | -0.4495 Cr | 0.0000 Cr | 0.0000 Cr |
| 2022-03-31 | 41.0013 Cr | -16.6264 Cr | -9.4771 Cr | 27.2936 Cr | 14.3764 Cr | 43.2556 Cr | -13.7077 Cr | 36.4081 Cr | -9.0156 Cr | 0.0000 Cr | 0.0000 Cr |
| 2021-03-31 | 132.6144 Cr | 55.7162 Cr | -162.2426 Cr | 124.8867 Cr | 26.9368 Cr | 28.8792 Cr | -7.7277 Cr | 25.1115 Cr | -168.9746 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 180.26 Cr | 113.64 Cr | 66.62 Cr | 0.3696 | 30.96 Cr | 25.58 Cr | 19.14 | 40.04 Cr | 0.1419 |
| 2025-09-30 | 192.75 Cr | 107.31 Cr | 85.44 Cr | 0.4433 | 24.79 Cr | 20.13 Cr | 15.06 | 32.67 Cr | 0.1044 |
| 2025-06-30 | 131.90 Cr | 74.15 Cr | 57.75 Cr | 0.4378 | 3.92 Cr | 9.60 Cr | 7.18 | 18.79 Cr | 0.0728 |
| 2025-03-31 | 194.97 Cr | 128.93 Cr | 66.04 Cr | 0.3387 | 24.29 Cr | 21.00 Cr | 15.71 | 35.76 Cr | 0.1077 |
| 2024-12-31 | 176.86 Cr | 110.20 Cr | 66.66 Cr | 0.3769 | 12.95 Cr | 19.60 Cr | 14.66 | 30.30 Cr | 0.1108 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 21.99 Cr | 214.20 Cr | 236.19 Cr | 96.57 Cr | 106.67 Cr | 485.69 Cr | 172.07 Cr | 768.10 Cr | 173.79 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 156.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -560.95 Cr |
| 2025-03-31 | 80.10 Cr | 98.77 Cr | 164.19 Cr | 112.22 Cr | 100.49 Cr | 451.72 Cr | 151.09 Cr | 715.72 Cr | 154.77 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 134.19 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -494.21 Cr |
| 2024-09-30 | 78.43 Cr | 55.76 Cr | 134.19 Cr | 67.73 Cr | 120.01 Cr | 391.48 Cr | 149.58 Cr | 660.46 Cr | 166.25 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 9.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 20.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 19.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 3.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Joint MD, Head of Research, Development & Operations and Whole-Time Director
Manu Chaudhary
Gender: Not Specified
Year Born: 1969
Vice President & Head of CAAR Division
Ajeet Kapoor
Gender: male
Year Born:
CTO & Executive Time Director
Akshansh Chaudhary
Gender: male
Year Born: 1993
CEO, Head of Legal, Regulatory Dept. & Whole-Time Director
Ashutosh Jain
Gender: male
Year Born: 1977
Chief General Manager of Administration
Jitendra Singh
Gender: male
Year Born:
President of Plant & Commercial
Manav Soni
Gender: male
Year Born:
Chairman, MD & Chief Financial Officer
Pawan Chaudhary
Gender: male
Year Born: 1964
Deputy MD, Head of Indian Marketing Operations & Whole-Time Director
Peeyush Jain
Gender: male
Year Born: 1971
Chief General Manager of Secretarial & Banking
Rakesh Pandit
Gender: male
Year Born:
Company Secretary & Compliance Officer
Neha Kodan
Gender: female
Year Born:
FAQs about Venus Remedies Limited
Who is the CEO of the company?
The CEO is Ashutosh Jain.
What is the current market price of the stock?
The current price is ₹651.45.
What is the 52-week price range?
The range is ₹277.95-839.95.
What is the market capitalization of the company?
The market capitalization is ₹870.79 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 11.41.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Venus Remedies Limited (ISIN: INE411B01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹870.79 crores and an average daily volume of 32,486 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.